Armatus Announces Groundbreaking Data Supporting TVR110, a Vectorized MicroRNA Therapy for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Armatus has published data in Molecular Therapy Nucleic Acids describing TVR110, a first-in-class vectorized microRNA for CMT1A.
Yahoo Finance

Vectorized Antibodies By In Vivo Expression Of DNA Or RNA Market Research 2025 | Overcoming Antibody Therapy Limitations with Vectorized Innovations

Vectorized antibodies hold promise to overcome many of these limitations and provide a great opportunity for DNA and RNA technology companies to enter larger markets compared with the rare disease ...
Healio

FDA grants fast track designation to vectorized antibody to treat ALS

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...
FierceBiotech

AbbVie, Voyager add Parkinson’s disease, $65M to ‘vectorized’ antibody pact

A year after AbbVie and Voyager Therapeutics teamed up on Alzheimer’s disease, they are expanding their partnership to include Parkinson’s disease and other diseases in which misfolded alpha-synuclein ...
manilatimes

PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA ...

PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology ...